retatrutide mechanism glp-1 gip glucagon triple agonist Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data The Road towards Triple Agonists:

Inclusion criteria: Studies on GLP-1 and inflammation Arthritis-related experimental models Publications from 20052025 Exclusion criteria: Non-peer-reviewed articles Studies lacking quantitative data Researchers extracted data about cytokine levels, receptor expression, and cartilage outcomes

By weeks two and three, GIP receptor effects become more pronounced

By activating GLP-1Rs on glial cells, these agents suppress pro-inflammatory cytokines (IL-1, TNF-) and block NF-B-mediated inflammatory cascades [10,24]

Early generic entrants may price products at higher margins initially, with costs declining as additional manufacturers receive Health Canada approval and enter the Canadian market

It addresses the constellation of metabolic risk factors collectively known as metabolic syndrome, which is the primary driver of cardiovascular disease, type 2 diabetes, and premature death in patients with obesity